BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19169006)

  • 1. Recent therapeutic strategies improve renal outcome in patients with IgA nephropathy.
    Komatsu H; Fujimoto S; Hara S; Fukuda A; Fukudome K; Yamada K; Sato Y; Kitamura K
    Am J Nephrol; 2009; 30(1):19-25. PubMed ID: 19169006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivariate analysis of prognostic factors and effect of treatment in patients with IgA nephropathy.
    Komatsu H; Fujimoto S; Hara S; Sato Y; Yamada K; Eto T; Nakao H
    Ren Fail; 2005; 27(1):45-52. PubMed ID: 15717634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study.
    Manno C; Strippoli GF; D'Altri C; Torres D; Rossini M; Schena FP
    Am J Kidney Dis; 2007 Jun; 49(6):763-75. PubMed ID: 17533019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Point of no return (PNR)" in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR.
    Komatsu H; Fujimoto S; Sato Y; Hara S; Yamada K; Morita S; Eto T
    J Nephrol; 2005; 18(6):690-5. PubMed ID: 16358226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function.
    Moriyama T; Honda K; Nitta K; Yumura W; Nihei H
    Clin Exp Nephrol; 2004 Sep; 8(3):237-42. PubMed ID: 15480901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy?
    Courtney AE; McNamee PT; Nelson WE; Maxwell AP
    Nephrol Dial Transplant; 2006 Dec; 21(12):3550-4. PubMed ID: 16968729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presentation, prognosis and outcome of IgA nephropathy in Indian adults.
    Chacko B; John GT; Neelakantan N; Korula A; Balakrishnan N; Kirubakaran MG; Jacob CK
    Nephrology (Carlton); 2005 Oct; 10(5):496-503. PubMed ID: 16221102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary glomerulonephritis: an update on renal survival and determinants of progression.
    Moranne O; Watier L; Rossert J; Stengel B;
    QJM; 2008 Mar; 101(3):215-24. PubMed ID: 18245806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.
    Draman CR; Kong NC; Gafor AH; Rahman AF; Zainuddin S; Mustaffa WM; Radzi AM; Shamsul AS
    Singapore Med J; 2008 Nov; 49(11):924-9. PubMed ID: 19037561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesangial C4d deposition: a new prognostic factor in IgA nephropathy.
    Espinosa M; Ortega R; Gómez-Carrasco JM; López-Rubio F; López-Andreu M; López-Oliva MO; Aljama P
    Nephrol Dial Transplant; 2009 Mar; 24(3):886-91. PubMed ID: 18842673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latent IgA deposition from donor kidney is the major risk factor for recurrent IgA nephropathy in renal transplantation.
    Moriyama T; Nitta K; Suzuki K; Honda K; Horita S; Uchida K; Yumura W; Tanabe K; Toma H; Nihei H; Yamaguchi Y
    Clin Transplant; 2005; 19 Suppl 14():41-8. PubMed ID: 15955168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study.
    Wakai K; Kawamura T; Endoh M; Kojima M; Tomino Y; Tamakoshi A; Ohno Y; Inaba Y; Sakai H
    Nephrol Dial Transplant; 2006 Oct; 21(10):2800-8. PubMed ID: 16822793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
    Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
    Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cigarette smoking and progression of IgA nephropathy.
    Yamamoto R; Nagasawa Y; Shoji T; Iwatani H; Hamano T; Kawada N; Inoue K; Uehata T; Kaneko T; Okada N; Moriyama T; Horio M; Yamauchi A; Tsubakihara Y; Imai E; Rakugi H; Isaka Y
    Am J Kidney Dis; 2010 Aug; 56(2):313-24. PubMed ID: 20471735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of tonsillectomy with modified high-dose intravenous methylprednisolone therapy in patients with IgA nephropathy].
    Sugawara K; Takeda K; Nakai K; Takahashi N; Adachi T; Fukuda T; Miura S
    Nihon Jinzo Gakkai Shi; 2008; 50(8):1017-23. PubMed ID: 19172803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgA nephropathy in kidney allograft recipients-therapeutic perspective.
    Pazik J; Baczkowska T; Lewandowski Z; Lewandowska D; Ostrowska J; Perkowska Ptasińska A; Mróz A; Miszewska-Szyszkowska D; Rowinski W; Durlik M
    Transplant Proc; 2006; 38(1):112-4. PubMed ID: 16504678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tonsillectomy delays progression of advanced IgA nephropathy to end-stage kidney disease.
    Komatsu H; Fujimoto S; Kikuchi M; Sato Y; Kitamura K
    Ren Fail; 2012; 34(4):448-53. PubMed ID: 22260382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of repeated lead chelation therapy in progressive non-diabetic chronic kidney diseases.
    Lin-Tan DT; Lin JL; Yen TH; Chen KH; Huang YL
    Nephrol Dial Transplant; 2007 Oct; 22(10):2924-31. PubMed ID: 17556414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Useful indicators for performing renal biopsy in adult patients with isolated microscopic haematuria.
    Shen P; He L; Jiang Y; Wang C; Chen M
    Int J Clin Pract; 2007 May; 61(5):789-94. PubMed ID: 17362478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tonsillectomy does not prevent a progressive course in IgA nephropathy.
    Rasche FM; Schwarz A; Keller F
    Clin Nephrol; 1999 Mar; 51(3):147-52. PubMed ID: 10099887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.